Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Probiotix HealthFRA:X90 29 Cash Ratio is 3.98 as of Dec. 2025, which is 18% below its 10-year median of 4.83. GuruFocus rates FRA:X90 with a GF Score™ of 29/100 and a GF Value™ of €0.08. The stock has 4 warning signs investors should review. Among 1,382 Biotechnology companies, Probiotix Health ranks better than 57.67% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Probiotix Health Cash Ratio Related Terms
Probiotix Health Cash Ratio Historical Data
* Premium members only.
The historical data trend for Probiotix Health's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:X90 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Probiotix Health's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Probiotix Health Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Probiotix Health's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Probiotix Health's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probiotix Health (FRA:X90) has a Cash Ratio of 3.98 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Probiotix Health and its competitors. This is 18% below median its historical median of 4.83. Over the past decade, Probiotix Health's Cash Ratio has ranged from 2.65 to 8.48. According to the industry distribution chart, Probiotix Health ranks #585 out of 1382 companies in the Biotechnology industry, placing it in the top 42.3%.
Is Probiotix Health's Cash Ratio too high?
Probiotix Health's current Cash Ratio of 3.98 is 18% below median its 10-year median of 4.83. Over the past 10 years, this metric has ranged from a low of 2.65 to a high of 8.48. The Biotechnology industry median Cash Ratio is 2.95. Probiotix Health's value of 3.98 is 35.1% above this industry median. Based on the distribution chart, Probiotix Health ranks #585 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Probiotix Health has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Probiotix Health's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Probiotix Health ranks #585 out of 1382 companies for Cash Ratio. This puts Probiotix Health in the upper half of its industry. The industry median Cash Ratio is 2.95. Probiotix Health's value of 3.98 is 35.1% above this benchmark. Historically, Probiotix Health's own Cash Ratio has ranged from 2.65 to 8.48 over the past decade. While the company's 10-year median is 4.83 vs. the industry median of 2.95, Probiotix Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Probiotix Health's current Cash Ratio of 3.98 is 35.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Probiotix Health and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Probiotix Health's current Cash Ratio is 3.98, which is 18% below median its own 10-year median of 4.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Probiotix Health (FRA:X90) has a current Cash Ratio of 3.98. The stock's GF Value™ is €0.08, compared to a current price of €0.09 — trading 11.3% above its estimated fair value. The current Cash Ratio is 3.98, which is 18% below median its 10-year median of 4.83 and 35.1% above the Biotechnology industry median of 2.95. Probiotix Health's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Probiotix Health (FRA:X90), the current Cash Ratio is 3.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Probiotix Health (FRA:X90) Overvalued in 2026?
Based on GuruFocus' analysis, Probiotix Health stock appears to be overvalued.
The current stock price of €0.09 is trading 11.3% above its estimated GF Value™ of €0.08.
Key valuation signals for FRA:X90:
Cash Ratio: 3.98 (18% below median its 10-year median of 4.83)
GF Value™: €0.08 vs. price of €0.09 (11.3% above fair value)
Industry Position: 35.1% above the Biotechnology median (#585 of 1382)
No single metric tells the full story. See the FRA:X90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
29GF Score
Get the complete analysis for FRA:X90
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:X90 has been successfully added to your 
